Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

This study has been terminated.
(The study was terminated early due to low accrual.)
Sponsor:
Information provided by (Responsible Party):
Keisuke Shirai, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT01783431
First received: January 25, 2013
Last updated: May 30, 2014
Last verified: May 2014
  Purpose

This study is for subjects with a type of skin cancer called melanoma. The main purpose of this study is to examine the safety of the study drug (Poly-ICLC) in patients with your disease. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for your disease.


Condition Intervention
Melanoma
Drug: Poly ICLC
Procedure: leukapheresis

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic and/or Unresectable Melanoma

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    - safety of this treatment by evaluating the qualitative and quantitative toxicities in this group of patients through adverse event reporting


Secondary Outcome Measures:
  • Feasibility [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    - feasibility of generating dendritic cells and administering these cells as a vaccine to patients

  • Anti-tumor Response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    anti-tumor response after vaccination, measured by changes in tumor burden and overall survival

  • Immunological Responses [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    - immunological responses after vaccination (antigen-specific T cell cytokine production, antigen-specific T cell frequencies by tetramer analysis, and DTH reactions)


Enrollment: 1
Study Start Date: October 2012
Study Completion Date: November 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Leukapheresis and Poly-ICLC
Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
Drug: Poly ICLC
Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
Other Name: Poly ICLC
Procedure: leukapheresis
Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.

Detailed Description:

Dendritic cells are cells that are present in your body's immune system that help your body fight disease. This is a vaccine trial, as your own cells will be extracted (removed), treated in a lab, then re-administered to your body with the study drug in hopes of creating an immune response to the disease. It is not guaranteed that your disease burden will be reduced by participating in this trial.TScreening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed diagnosis of melanoma that is metastatic and/or unresectable. If the histologic diagnosis is based on a metastatic site, the histology must be compatible with melanoma.
  • Patients must be HLA-A2 positivity by serological testing.
  • Patients must have measurable disease per RECIST 1.1
  • Patients may have had prior cancer therapy. Patients do not need to demonstrate progression to be considered for this trial.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  • Age ≥ 18 years.
  • Patient must have an expected life expectancy greater than 3 months.
  • Signed, written IRB-approved informed consent.
  • Acceptable organ function:
  • Bilirubin ≤ 3 times upper limit of normal (CTCAE Grade 2 baseline)
  • AST (SGOT), ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)
  • Serum creatinine ≤1.5 XULN (CTCAE Grade 1 baseline)
  • Acceptable hematologic status:
  • Absolute neutrophil count ≥ 1000 cells/mm3,
  • Platelet count ≥ 75,000 (plt/mm3), (CTCAE Grade 1 baseline)
  • Hemoglobin ≥ 9 g/dL.
  • Urinalysis with no clinically significant abnormalities.
  • PT and PTT ≤ 1.5 X ULN after correction of nutritional deficiencies that may contribute to prolonged PT/PTT.

Exclusion Criteria:

  • Patients must not have any serious uncontrolled acute or chronic medical condition that would interfere with this treatment. Examples would include active acute or chronic infection requiring antibiotics, uncontrolled cardiovascular, endocrine, or infectious disease.
  • Patients must not have significant ongoing cardiac problems, myocardial infarction within the last six months, uncontrolled hypertension, unstable angina, uncontrolled arrhythmia or congestive heart failure.
  • Surgery less than or equal to 14 days prior to study registration
  • Patients who have had prior radiation or chemotherapy in which the last treatment administration is less than or equal to 28 days prior to registration. Patients who have had prior treatment with ipilimumab or Interleukin-2 will be allowed as long as this 28 day wash-out period is followed.
  • Patients who are breast feeding or have a positive pregnancy test (if female).
  • Patients with active CNS lesions are excluded (i.e., those with radiographically unstable, symptomatic lesions). However, a patient treated with stereotactic therapy or surgery is eligible if the patient remains without evidence of disease progression in the brain and is stable for 1 month. Whole brain radiotherapy is not allowed, with the exception of patients who have had definitive resection or stereotactic therapy of all radiologically detectable parenchymal lesions.
  • Patients must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol treatment.
  • Due to the undetermined effect of this treatment regimen in patients with HIV-1 infection and the potential for serious interaction with anti-HIV medications, patients known to be infected with HIV are not eligible for this study.
  • Due to the possibility of harm to a fetus or nursing infant from this treatment regimen, patients must not be pregnant or nursing. Women and men of reproductive potential must have agreed to use an effective contraceptive method.
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01783431

Locations
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Principal Investigator: Keisuke Shirai, MD Medical University of South Carolina
  More Information

No publications provided

Responsible Party: Keisuke Shirai, Principal Investigator, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT01783431     History of Changes
Other Study ID Numbers: 101838
Study First Received: January 25, 2013
Last Updated: May 30, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Poly ICLC
Interferon Inducers
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 29, 2014